In vivo CAMPATH-1 monoclonal antibodies: A novel mode of therapy for acute graft-versus-host disease
✍ Scribed by Varadi, Gabor; Or, Reuven; Slavin, Shimon; Nagler, Arnon
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 205 KB
- Volume
- 52
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
✦ Synopsis
CHOP, COP plui doxorubicin. ,'According to NCI criteria (Cheson el al. 151).
(PD) was registered in one patient. Median time to disease progression for patients in PR or SD was 9 months (range, 1-14 months) (Table I).
The results of the prehent study, although based on a small number of patients, arc in keeping with good compliance with this novel "fully-oral" drug regimen, including IDA given on alternate days. By contrast, the administration of IDA on alternate days, producing long-standing but lower peaks of idarubicinol (IDAol), the active metabolite, may result either in reduced toxicity or in enhanced antineoplastic activity [I].
Finally, the tendency for physicians trcating patients with low-grade malignancy to prefer combination regimens suggests that oral IDA coinbined with alkylating agent? could be worthy of exploration. particularly in elderly patients who are less disposed to receive more i'ntcnsive regimens. This is especially true in CLL disease, in which dose intensity and schedule are not mandatory for delivering therapy with curative intent.